98%
921
2 minutes
20
Recent innovations in immunoregulatory treatments have demonstrated both the impressive potential and vital role of T cells in fighting cancer. These treatments come at a cost, with systemic side effects including life-threatening autoimmunity and immune dysregulation the norm. Here, we developed an approach to locally synthesize immune therapies and in this way, avoid systemic toxicity. Rather than just encapsulating cytokines, we endowed our nanoparticles with transcriptional and translational machinery to cytokines locally, , and on demand (activated by light). We demonstrated the capabilities of these particles and , in a mouse model of melanoma, and showed that tumor-infiltrating T cells were more highly activated in the context of these "microfactory" particles that make the synthetic cytokine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7748250 | PMC |
http://dx.doi.org/10.1039/d0mh00755b | DOI Listing |
Clin Cancer Res
September 2025
University of Southampton, Southampton, United Kingdom.
Purpose: Varlilumab is a CD27 agonist antibody, delivering a T-cell costimulation. Preclinical studies show agonistic CD27 antibodies can activate intratumoral T-cells to release chemokines and cytokines to augment macrophage-dependent tumor killing induced by CD20 antibodies, i.e.
View Article and Find Full Text PDFFront Immunol
September 2025
Bacterial Scientific Area, GSK Vaccine, Siena, Italy.
Background: Protein-polysaccharide conjugate vaccines rely on the induction of T-cell-dependent responses that support germinal center (GC) reactions to potentiate the expansion of antigen-specific memory B-cell (MBC) populations and high-avidity antibody responses. The effects of adjuvants on B-cell and antibody responses are well described for protein antigens but remain largely unexplored for conjugated polysaccharidic antigens.
Methods: We assessed the effects of five adjuvants present in licensed vaccines (AS01, AS03, AS04, and aluminum hydroxide [Alum]) or under clinical evaluation (AS37) on the magnitude and quality of antigen-specific antibody responses and local/systemic B-cell responses.
Pathol Res Pract
August 2025
Urology Research Center, Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Management of non-muscle-invasive bladder cancer (NMBIC) typically involves transurethral resection of bladder tumor (TURBT) followed by intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, 30-50 % of patients may not respond to BCG or experience recurrence. High-dose vitamin C (VitC) has shown promise in improving the outcome of immunotherapies such as immune checkpoint blockade.
View Article and Find Full Text PDFJ Agric Food Chem
September 2025
School of Public Health, Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong Province 518060, PR China.
Sucralose, a common zero-calorie sweetener, may increase food allergy (FAs) risk via immune modulation, although its mechanisms remain poorly understood. This study investigates how sucralose exacerbates allergic responses in mice that are OVA-sensitized through specific immunologic mechanisms. Sucralose exposure markedly aggravated allergic symptoms, including diarrhea, elevated serum IgE, MCP-1, and mast cell mediators, and preferentially enhanced Th2 responses without affecting Th1 or Treg cytokine pathways.
View Article and Find Full Text PDFCell Rep Med
August 2025
Department of Medicine, The University of Chicago, Chicago, IL 60637, USA. Electronic address:
The detailed mechanisms underlying the regulatory significance of dietary components in modulating anti-tumor immunity remain largely unknown. Here, we apply a co-culture-based screening approach using a blood nutrient compound library and identify zeaxanthin (ZEA), a dietary carotenoid pigment found in many fruits and vegetables and known for its role in eye health, as an immunomodulator that enhances the cytotoxicity of CD8 T cells against tumor cells. Oral supplementation with ZEA, but not its structural isomer lutein (LUT), enhances anti-tumor immunity in vivo.
View Article and Find Full Text PDF